BOSTON / Oct 09, 2024 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David Henry, chief financial officer, will participate in a “Fireside Chat” at the 2024 Maxim Healthcare Virtual Summit. The virtual summit is being presented by Maxim Group LLC, from October 15th to 17th. Mr. Gudonis and Mr. Henry will be interviewed by Anthony Vendetti, Maxim’s Executive Managing Director of Research and Senior Healthcare Analyst on Wednesday, October 16th at 10:30 a.m. Eastern Time.
Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. To attend, just sign up to become an M-Vest member and stay tuned for more updates. Click here to reserve your seat.
Management is available for 1x1 meetings with investors. Please contact Kim Golodetz at LHA Investor Relations to schedule a meeting.
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.
Last Trade: | US$4.18 |
Daily Change: | 0.22 5.56 |
Daily Volume: | 295,918 |
Market Cap: | US$126.360M |
November 06, 2024 August 06, 2024 May 08, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB